Gout News

  • Canakinumab Reduces Gout Risk Without Changing SUA Levels Canakinumab, an interleukin 1-beta blocker, was associated with significantly lower risk for gout attacks when given quarterly, but did not change serum uric acid levels, a study has found.
  • EADV 2018 Global Estimates Belittle Burden of Skin Diseases A patient-driven project is underway to accurately measure skin diseases around the world so that melanoma and psoriasis are not rated as being less problematic than gout.

Gout Perspective